Background: In 2012, the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening, despite evidence that Black men are at a higher risk of prostate cancer-specific mortality (PCSM). We evaluated whether Black men of potentially screening-eligible age (55-69 years) are at a disproportionally high risk of poor outcomes.
Introduction
The United States Preventive Service Task Force (USPSTF) recommendations discouraging prostate-specific antigen (PSA) screening were largely based on two conflicting trials: The European Randomized Screening Trial for Prostate Cancer (ERSPC)-with results arguably in favor of PSA screening-and the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer trial-with results against PSA screening [1, 2] . Despite conflicting evidence on the benefits versus harms of PSA screening between the trials and the expectation that with more followup time the results from the ERSPC will continue to strengthen in support of PSA screening, there has been a significant decline in the overall use of PSA screening and there has been migration toward higher risk disease at diagnosis in the United States that coincides with USPSTF recommendations against PSA screening in 2012 [3] [4] [5] [6] .
This may disproportionately impact the outcomes of patients who are at higher risk of the potential harms from prostate cancer, especially for Black men who suffer from the highest rates of prostate cancer incidence and mortality [7] . The ERSPC trial did not report results by race and the PLCO only included 4% Black men, and therefore the USPSTF recommendations are based on trials that did not include enough Black men to make scientifically rigorous PSA screening recommendations according to race. Nevertheless, several major cancer organizations in the United States recommend shared decision-making for PSA screening, with specific attention to race. Specifically, the American Urological Association (AUA) recommends shared decisionmaking to undergo PSA screening for men age 55-69 years (with individualized plans for Black men younger than age 55 years) [8] , the American Society of Clinical Oncology (ASCO) recommends shared decision-making in men with a life expectancy > 10 years [9] , and the American Cancer Society (ACS) recommends the discussion of PSA screening to begin at age 50 years for men at average risk (and age 45 years for Black men) who are expected to live at least 10 years [10] .
Given the ongoing controversy surrounding PSA screening recommendations and the uncertainty of the differential impact of USPSTF recommendations on prostate cancer outcome by race, we performed a large contemporary study of a USA cohort using the Surveillance, Epidemiology and End Results (SEER) program to determine whether Black men of potentially screening-eligible age (age 55-69 years, as above) are at a disproportionally high risk of poor prostate cancer outcomes.
Methods

Study design
The SEER Program was used to identify a contemporary cohort of 390 259 men with prostate cancer diagnosed in the United States between 2004 and 2011 [11, 12] . Primary endpoint analyses focused on patients with localized disease; therefore, patients were excluded if they had metastatic disease (N ¼ 16 389-though these patients were included for secondary endpoint analysis of presentation with metastatic disease), missing Gleason score (N ¼ 13 948), or missing T stage (N ¼ 14 599), leaving N ¼ 345 323 patients available for primary endpoint analyses as displayed in Figure 1 . The study period began with 2004 since that was the first year Gleason scores were introduced to SEER [13] . The primary independent variable of interest in this study was race (Black versus non-Black), as stratified by PSA-screening eligibility, where patients age 55-69 years were considered eligible for screening based on AUA, ASCO, and ACS guidelines [8] [9] [10] . Other independent variables included in multivariable analyses were Gleason score, T stage, treatment type, age at diagnosis, education status, and income. Gleason score, as provided by the SEER program from 2004 to 2009 [13] , represented the highest score identified at surgery or at biopsy for non-surgically managed patients. From 2010 to 2011, both biopsy and pathologic Gleason scores were provided in SEER [13] , however, we categorized 2010-2011 scores according to the highest Gleason score at either biopsy or surgery to be consistent with grading patterns from 2004 to 2009. T stage was determined using the AJCC 6th edition as provided by the SEER program [11] . Treatment received was classified according to the National Comprehensive Cancer Network guidelines and included radical prostatectomy, radiation therapy (external beam radiation therapy and/or brachytherapy), or non-definitive treatment (including observation, expectant management, or androgen deprivation therapy alone) [3] . Age at diagnosis was included as a continuous variable. Income (computed as median household income) and educational status (computed as the percentage of residents !25 years of age with at least a high school education) were both determined at the county level by linking to the 2000 USA Census and included as continuous variables [14] . PSA was not included as an independent variable given recent evidence that a large proportion of PSA values in SEER may not be accurate, primarily due to errors in recording decimal points [15] .
Statistical analyses
Baseline patient characteristics by race were compared with the Wilcoxon rank-sum test or chi-squared test as appropriate.
The primary endpoint of this study was prostate cancer-specific mortality (PCSM). Secondary endpoints included stage of presentation (metastatic versus localized/non-metastatic disease) and receipt of definitive therapy. Multivariable Fine-Gray competing risks regression was used to model the association between race and PCSM, while multivariable logistic regression modeled the associations between Black race and stage at presentation and Black race and receipt of definitive therapy. To answer the main study question of whether or not race outcomes differed by PSA-screening eligibility, multivariable logistic regressions with interaction terms for race and PSA-screening eligibility (age 55-69 years versus not) were applied. Cumulative incidence plots were generated from the Fine-Gray analyses stratified by screening eligibility and were used to plot PCSM as a function of race.
P values were two-sided. The threshold of 0.05 was used to determine statistical significance. All statistical analyses were performed using STATA 13.1 (StataCorp, College Station, TX). This study was approved by the Dana-Farber/Harvard Cancer Center institutional review board; a waiver for informed consent was obtained.
Results
Baseline characteristics
There were 345 323 men with localized prostate cancer in this study. Among patients with localized disease, 191 552 (55%) were eligible for PSA screening (age 55-69 years), while 153 771 (45%) were not eligible for PSA screening. Baseline characteristics including age at diagnosis, education, income, Gleason score, T stage, and initial management type were all clinically similar but statistically different when comparing across race for Black versus non-Black men (supplementary Table S1 , available at Annals of Oncology online). Notably, Black patients were younger and more likely to be of screening age (age 55-69 years), had lower incomes ($42 000 versus $46 000), had less Gleason 6 disease (43% versus 46%) but more T1 stage disease (67% versus 60%), and were less likely to receive definitive therapy as initial management (72% versus 73%) when compared to non-Black men (all P < 0.001 [supplementary 
Racial disparities stratified by PSA-screening eligibility
After adjusting for demographic and clinical characteristics, significant interactions between race and PSA-screening eligibility were noted for the primary endpoint of prostate cancer-specific mortality (P interaction ¼ 0.01) and secondary endpoint of presentation with metastatic disease (P interaction < 0.001), but not for the secondary endpoint of receipt of definitive therapy (P interaction ¼ 0.48) ( Table 2) .
The race and PSA-screening eligibility interaction for presentation with metastatic disease demonstrated that Black men had disproportionately higher odds of metastatic disease compared to non-Black men in the potentially PSA-screening eligible group compared to those not eligible for screening (AOR 1.76; 95% CI: 1.65-1.87 versus 1.55; 95% CI 1.47-1.65; P interaction < 0.001 [ Table 2 ]). Furthermore, the race and PSA-screening eligibility interaction for the primary endpoint of PCSM demonstrated that Black men incurred disproportionately higher prostate cancer mortality in the PSA-screening eligible group compared to those not eligible for screening (AHR 1.53; 95% CI 1.37-1.70 versus 1.25; 95% CI 1.14-1.37; P interaction ¼ 0.01). Of note, cumulative incidence plots of percent PCSM demonstrate that projected out to 95-month follow-up, there was only a trend toward higher rates of PCSM for Black versus non-Black men among those not eligible for screening (P ¼ 0.06 [ Figure 2 ]), while rates of PCSM were much greater for Black versus non-Black men among those eligible for PSA screening (P < 0.001 [ Figure 3] ).
Discussion
In this study of a large contemporary cohort of patients diagnosed with prostate cancer in the United States, we found that racial disparities in prostate cancer outcome for Black men are significantly worse among patients potentially eligible for PSA screening (age 55-69 years) when compared to patients not eligible for screening. Strikingly, when comparing rates of metastatic disease and death due to prostate cancer in PSA-screening eligible groups to those not eligible for PSA screening, Black men experienced excess disproportionate rates of metastatic disease and prostate cancer mortality in the potentially PSA-screening eligible population. Specifically, in the PSA-screening-eligible group, Black men compared to non-Black men experienced a nearly 30% increase in disparity of presentation with metastatic disease and a nearly 20% increase in disparity of prostate cancer hazard when compared to the disparity rates in the group not eligible for PSA screening. These results raise the possibility that Black men of screening age (55-69 years) could be disproportionately impacted by recommendations to end PSA screening and suggest that Black race should be included in national authoritative PSA screening guidelines. Our results are clinically significant, and may be informative in guiding current clinical approaches to PSA screening recommendations. The USPSTF recommends against PSA-based screening for prostate cancer, regardless of age-group, life-expectancy, race, or any other demographic or clinical characteristic-and this recommendation has led to a significant decline in the use of PSA screening in the United States. However, the evidence presented in this study that Black patients experienced more disproportionate rates of metastatic disease and PCSM in the potentially PSAscreening eligible group compared to those not eligible for screening strongly argues for including race as a factor in national PSA screening guidelines and argues against the USPSTF approach. We would argue that our results support incorporation of Black race into PSA screening among men aged 55-69 years. Early diagnosis of potentially aggressive prostate cancers among Black men has the potential to reduce prostate cancer mortality in this group and also reduce disparities in prostate cancer outcome, which has been a major goal for many major cancer organizations. Our work contributes quantitative evidence in support of the growing paradigm shift that including race in PSA screening guidelines could potentially save lives of many Black men [16] . Our data also have significant implications for the interpretation of the major PSA screening trials, including the ERSPC and PLCO trials. In light of our results demonstrating excess disparity in a screening eligible population, it is highly likely that the number needed to screen and number needed to treat to save one Black man's life among men eligible for PSA screening (age 55-69 years) would be lower than the numbers reported in the ERSPC-and potentially in favor of routine PSA screening among Black men [17] . Specifically, given that Black men present with higher incidence of prostate cancer, more aggressive disease, and higher rates of PCSM than non-Black men [7, 18, 19] , Black men therefore would have likely benefited to a greater extent from screening and treatment than trial populations that were largely white.
The PLCO on the other hand did not show differences in PCSM by PSA-screening status and was the major trial whose results argue against PSA screening [2] , however the trial was significantly limited by prescreening and contamination [20] , and the trial was more of a comparison of annual screening versus occasional screening rather than screening versus no screening. Lastly, the PLCO only included only 4% Black men.
Although the USPSTF does acknowledge that results from the ERSPC and PLCO are limited since they include few Black men, the USPSTF points to evidence from the Prostate Cancer Intervention Versus Observation Trial (PIVOT), where 30% of enrollees were Black and there were no race-based differences in outcome due to treatment of prostate cancer in Black men compared to white men [21] , as a factor for not incorporating race into PSA recommendations. However, the fact that treatment had a similar effect regardless of race in a randomized trial of mainly low-risk men does not address the primary concern that Black patients tend to present with more advanced disease and therefore may be in need of greater screening.
Our results must be viewed within the limitations of the study. First, we were not able to adjust for PSA in our multivariable analyses due to SEER recording errors in this variable [15] .
Second the median follow-up of our study was only 42 months. Nevertheless, this was still enough time to see differences in PCSM among patients by race and screening status. Another limitation of this study is that SEER does not provide information on the potential harms of PSA screening, such as biopsy related infections, anxiety, cost, loss of time, anxiety, or pain.
Racial disparities in prostate cancer outcome among Black men are much worse in PSA-screening eligible populations. These results raise the possibility that Black men of screening age (55-69 years) could be disproportionately impacted by recommendations to end PSA screening and suggest that it is likely that the number needed to screen and number needed to treat to save one Black man's life among men eligible for PSA screening (age 55-69 years) would be lower than the numbers reported in the PSA screening trials. Our results support incorporation of Black race into decision-making about screening men aged 55-69 years.
